
On 14 January, the European Commission issued marketing approval for Flucelvax Tetra, the first cell-based, quadrivalent influenza vaccine. Pharmafocus spoke …

Seqirus has made it known that its new cell-based seasonal influenza vaccine Flucelvax Tetra has been approved by the European …
Despite the severity of the flu season, just 37.1% of American adults received the flu vaccine this year, according to …

The FDA has announced that it has approved the first single-dose flu drug with a novel mechanism of action in …

Public Health England has revealed that an enhanced, “adjuvanted” vaccine is to be made available for over-65s this winter, and …

Pfizer has announced a partnership with German biotech firm BioNTech after signing a multi-year deal worth $425 million to develop …

Roche is celebrating the news that its investigational influenza drug baloxavir marboxil performed well at Phase 3, meeting its primary …

One of the major challenges in delivering vaccinations to all parts of the globe is the need to keep the …

The US Centers for Disease Control and Prevention (CDC) has now recommended AstraZeneca’s FluMist as an option for doctors for …

The sometimes poor efficacy of influenza vaccines may be due to poor immune response and a patient’s wider immune history, …

The Bill & Melina Gates Foundation had already invested $52 million in CureVac, back in 2015, and has now doubled …

Researchers in Japan have achieved a notable success in a Phase 3 clinical trial to determine whether a new vaccine …

As we come to the end of January, it’s Friday again – time for another rundown of the top ten …

Research led by Georgia State University has enabled the development of a universal vaccine for influenza A viruses, proven to …

Seqirus, an influenza vaccine specialist subsidiary of global biotech firm CSL, has announced a £40 million investment into a new …